Effect of L-Carnitine on Troponin, IL6 and HS– CRP levels after Coronary Artery Bypass Graft Surgery
Journal of Cellular & Molecular Anesthesia,
Vol. 4 No. 2 (2019),
29 October 2019
,
Page 41-48
https://doi.org/10.22037/jcma.v4i2.26169
Abstract
Background: L-carnitine seems to be able to prevent complications after heart surgery using Cardiopulmonary bypass (CPB) and the adverse effects of pump usage. This study aimed to evaluates the effects of L-carnitine on cardiac biomarkers and operation characteristics after coronary artery bypass graft (CABG) surgery.Methods and materials: In this randomized triple-blinded, sixty patients undergoing elective CABG surgery were divided into three equal groups to receive 2gr oral L-carnitine (group A), 5gr oral L-carnitine (group B) and placebo (group C) 2 hours before surgery. IL-6, creatinine, and high sensitivity C-reactive protein (HS–CRP) levels, CK-MB, cardiac troponin and inotrope administration in ICU or after CPB were recorded for all patients at baseline levels and at 8 or 24 hours postoperatively.Results: There was an evidence of a significant difference in CPK-MB level and number of red blood cell packed used in group A was lower than group C (p<0.05). The cardiac troponin level 8 hours after surgery significantly decreased in two treatment groups in comparison to group C (p<0.05). The need for inotropic support after weaning from CPB, in B group was statistically higher than C group (p=0.021).Conclusion: Although L-carnitine adjunct therapy appears not to be associated with IL-6 and HS–CRP levels, it had beneficial effects on cardiac troponin and CPK-MB levels.
Keywords: Coronary artery bypass graft surgery, IL-6, HS–CRP levels, L-carnitine, Troponin
How to Cite
References
Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1-25.
Ciolac EG. High-intensity interval training and hypertension: maximizing the benefits of exercise? Am J Cardiovasc Dis. 2012;2(2):102-10.
lavich M, Patel RS. Coronary artery spasm: Current knowledge and residual uncertainties. International journal of cardiology Heart & vasculature. 2016;10:47-53.
Fan LC, Liang S, Lu HW, Fei K, Xu JF. Efficiency and safety of surgical intervention to patients with Non-Cystic Fibrosis bronchiectasis: a meta-analysis. Scientific reports. 2015;5:17382.
Roach GW, Kanchuger M, Mangano CM, Newman M, Nussmeier N, Wolman R, Aggarwal A, Marschall K, Graham SH, Ley C. Adverse cerebral outcomes after coronary bypass surgery. N Engl J Med. 1996;335(25):1857-63.
McKhann GM, Goldsborough MA, Borowicz LM Jr, Selnes OA, Mellits ED, Enger C, Quaskey SA, Baumgartner WA, Cameron DE, Stuart RS, Gardner TJ. Cognitive outcome after coronary artery bypass: a one-year prospective study. Ann Thorac Surg. 1997;63(2):510-5.
Etievent JP, Chocron S, Toubin G, Taberlet C, Alwan K, Clement F, Cordier A, Schipman N, Kantelip JP. Use of cardiac troponin I as a marker of perioperative myocardial ischemia. Ann Thorac Surg. 1995;59(5):1192-4.
Sawa Y, Ichikawa H, Kagisaki K, Ohata T, Matsuda H. Interleukin-6 derived from hypoxic myocytes promotes neutrophil-mediated reperfusion injury in myocardium. J Thorac Cardiovasc Surg. 1998;116(3):511-7.
Ucar HI, Tok M, Atalar E, Dogan OF, Oc M, Farsak B, Guvener M, Yilmaz M, Dogan R, Demircin M, Pasaoglu I. Predictive significance of plasma levels of interleukin-6 and high-sensitivity C-reactive protein in atrial fibrillation after coronary artery bypass surgery. Heart Surg Forum. 2007;10(2):E131-5.
Seino Y, Ikeda U, Ikeda M, Yamamoto K, Misawa Y, Hasegawa T, Kano S, Shimada K. Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine. 1994;6(1):87-91.
Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101(15):1767-72.
Olsen PC, Ferreira TP, Serra MF, Farias-Filho FA, Fonseca BP, Viola JP, Cordeiro RS, Silva PM, Costa JC, Martins MA. Lidocaine-derivative JMF2-1 prevents ovalbumin-induced airway inflammation by regulating the function and survival of T cells. Clin Exp Allergy. 2011;41(2):250-9.
Sayeed MM. Inflammatory/cardiovascular-metabolic responses in a rat model of burn injury with superimposed infection. Shock. 2005;24 Suppl 1:40-4.
Windgassen EB, Funtowicz L, Lunsford TN, Harris LA, Mulvagh SL. C-reactive protein and high-sensitivity C-reactive protein: an update for clinicians. Postgrad Med. 2011;123(1):114-9..
Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499-511.
Christenson RH, Duh SH, Newby LK, Ohman EM, Califf RM, Granger CB, Peck S, Pieper KS, Armstrong PW, Katus HA, Topol EJ. Cardiac troponin T and cardiac troponin I: relative values in short-term risk stratification of patients with acute coronary syndromes. GUSTO-IIa Investigators. Clin Chem. 1998;44(3):494-501.
Zacharowski K, Blackburn B, Thiemermann C. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol. 2001;418(1-2):105-10.
Flanagan JL, Simmons PA, Vehige J, Willcox MD, Garrett Q. Role of carnitine in disease. Nutr Metab (Lond). 2010;7:30.
Cruz WMS, Guimarães SMS, Maciel GC, Huguenin ABA, Carvalho MEM, Costa BO, Silva GAD, Colafranceschi AS, Scalco FB, Ribeiro M. L-carnitine supplementation in the recovery of plasma L-carnitine in patients with heart failure submitted to coronary artery bypass grafting. An Acad Bras Cienc. 2018;90(3):3099-3104.
Sun P, Jin M, Jiao L, Monroig Ó, Navarro JC, Tocher DR, Betancor MB, Wang X, Yuan Y, Zhou Q. Effects of dietary lipid level on growth, fatty acid profiles, antioxidant capacity and expression of genes involved in lipid metabolism in juvenile swimming crab, Portunus trituberculatus. Br J Nutr. 2019:1-36.
Shakeri A, Tabibi H, Hedayati M. Effects of L-carnitine supplement on serum inflammatory cytokines, C-reactive protein, lipoprotein (a), and oxidative stress in hemodialysis patients with Lp (a) hyperlipoproteinemia. Hemodial Int. 2010;14(4):498-504.
Suchitra M, , Ashalatha VL, Sailaja E, Rao AM, Reddy VS, Bitla AR, Sivakumar V, Rao PV. The effect of L-carnitine supplementation on lipid parameters, inflammatory and nutritional markers in maintenance hemodialysis patients. Saudi J Kidney Dis Transpl. 2011;22(6):1155-9.
Savica V, Santoro D, Mazzaglia G, Ciolino F, Monardo P, Calvani M, Bellinghieri G, Kopple JD. L-carnitine infusions may suppress serum C-reactive protein and improve nutritional status in maintenance hemodialysis patients. J Ren Nutr. 2005;15(2):225-30..
Wang ZY, Liu YY, Liu GH, Lu HB, Mao CY. l-Carnitine and heart disease. Life Sci. 2018;194:88-97.
Al-Yateem N, Rossiter R, Robb W, Ahmad A, Elhalik MS, Albloshi S, Slewa-Younan S. Mental health literacy among pediatric hospital staff in the United Arab Emirates. BMC Psychiatry. 2017;17(1):390..
Plume SK, O'Connor GT, Olmstead EM. As originally published in 1994: Changes in patients undergoing coronary artery bypass grafting: 1987-1990. Updated in 2000. Northern New England Cardiovascular Disease Study Group. Ann Thorac Surg. 2001;72(1):314-5.
Ferguson TB Jr, Hammill BG, Peterson ED, DeLong ER, Grover FL; STS National Database Committee. A decade of change--risk profiles and outcomes for isolated coronary artery bypass grafting procedures, 1990-1999: a report from the STS National Database Committee and the Duke Clinical Research Institute. Society of Thoracic Surgeons. Ann Thorac Surg. 2002;73(2):480-9
Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017;135(10):e146-e603.
Dastan F, Talasaz AH, Mojtahedzadeh M, Karimi A, Salehiomran A, Bina P, Jalali A, Aghaie Z. Potential Effect of L-Carnitine on the Prevention of Myocardial Injury after Coronary Artery Bypass Graft Surgery. J Tehran Heart Cent. 2015;10(2):74-9.
Iliceto S, Scrutinio D, Bruzzi P, D'Ambrosio G, Boni L, Di Biase M, Biasco G, Hugenholtz PG, Rizzon P. Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial. J Am Coll Cardiol. 1995;26(2):380-7.
Anand I, Chandrashekhan Y, De Giuli F, Pasini E, Mazzoletti A, Confortini R, Ferrari R. Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure. Cardiovasc Drugs Ther. 1998;12(3):291-9.
Lopaschuk G. Regulation of carbohydrate metabolism in ischemia and reperfusion. Am Heart J. 2000;139(2):s115-s9.
Opie LH. Role of carnitine in fatty acid metabolism of normal and ischemic myocardium. Am Heart J. 1979;97(3):375-88.
Shug AL, Thomsen JH, Folts JD, Bittar N, Klein MI, Koke JR, Huth PJ. Changes in tissue levels of carnitine and other metabolites during myocardial ischemia and anoxia. Arch Biochem Biophys. 1978;187(1):25-33.
Rizzon P, Biasco G, Di Biase M, Boscia F, Rizzo U, Minafra F, Bortone A, Siliprandi N, Procopio A, Bagiella E, et al. High doses of L-carnitine in acute myocardial infarction: metabolic and antiarrhythmic effects. Eur Heart J. 1989;10(6):502-8.
Rebouche CJ, Engel AG. Carnitine metabolism and deficiency syndromes. Mayo Clin Proc. 1983;58(8):533-40.
Suzuki Y, Kamikawa T, Kobayashi A, Masumura Y, Yamazaki N. Effects of L-carnitine on tissue levels of acyl carnitine, acyl coenzyme A and high energy phosphate in ischemic dog hearts. Jpn Circ J. 1981;45(6):687-94.
Singh RB, Niaz MA, Agarwal P, Beegum R, Rastogi SS, Sachan DS. A randomised, double-blind, placebo-controlled trial of L-carnitine in suspected acute myocardial infarction. Postgrad Med J. 1996;72(843):45-50.
Regitz V, Shug AL, Fleck E. Defective myocardial carnitine metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart diseases. Am J Cardiol. 1990;65(11):755-60.
Jacoba KGC, Abarquez RF, Topacio GO, Abola MT, Flores VB, Sison JM, Defensor V, Aliwalas D. Effect of L-Carnitine on the Limitation of Infarct Size in One-Month Postmyocardial Infarction Cases. Clin Drug Invest. 1996;11(2):90-6.
Rebuzzi AG, Schiavoni G, Lanza GA, Amico C, Natale A, Lucente M, Manzoli U. Rhythm of carnitine levels in serum and urine of normal subjects. Drugs Exp Clin Res. 1989;15(1):43-6.
Singh R, Niaz M, Agarwal P, Beegum R, Rastogi S, Sachan D. A randomised, double-blind, placebo-controlled trial of L-carnitine in suspected acute myocardial infarction. Postgrad Med J. 1996;72(843):45-50.
Ferrari R, Merli E, Cicchitelli G, Mele D, Fucili A, Ceconi C. Therapeutic effects of l‐carnitine and propionyl‐l‐carnitine on cardiovascular diseases: A review. Ann N Y Acad Sci. 2004;1033:79-91.
Vandewoude K, Blot S, Benoit D, Colardyn F, Vogelaers D. Invasive aspergillosis in critically ill patients: attributable mortality and excesses in length of ICU stay and ventilator dependence. J Hosp Infect. 2004;56(4):269-76.
Taniyama Y, Ito H, Iwakura K, Masuyama T, Hori M, Takiuchi S, et al. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol. 1997;30(5):1193-9..
Ishii H, Ichimiya S, Kanashiro M, Amano T, Imai K, Murohara T, Matsubara T. Impact of a Single Intravenous Administration of Nicorandil Before Reperfusion in Patients With ST-Segment–Elevation Myocardial Infarction. Circulation. 2005;112(9):1284-8.
Xue YZ1, Wang LX, Liu HZ, Qi XW, Wang XH, Ren HZ. L-carnitine as an adjunct therapy to percutaneous coronary intervention for non-ST elevation myocardial infarction. Cardiovasc Drugs Ther. 2007;21(6):445-8.
Dai Z, Zhu MM, Peng Y, Machireddy N, Evans CE, Machado R, Zhang X, Zhao YY. Therapeutic Targeting of Vascular Remodeling and Right Heart Failure in Pulmonary Arterial Hypertension with a HIF-2α Inhibitor. Am J Respir Crit Care Med. 2018;198(11):1423-1434.
Bauersachs J, Widder JD. Endothelial dysfunction in heart failure. Pharmacol Rep. 2008;60(1):119-26.
Maeda D, Ohishi S, Fujimoto W, Ohnishi T, Yasaka Y, Kawai H. Prognostic Impact of Proportional Pulse Pressure (PPP) in Patients with Acute Decompensated Heart Failure (ADHF). J Card Fail. 2016;9(22):S210.
Labinaz M, Mathias J, Pieper K, Granger CB, Lincoff AM, Moliterno DJ, et al. Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials. Eur Heart J. 2004;26(2):128-36.
Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, Neumann FJ, Robertson DH, DeLucca PT, DiBattiste PM, Gibson CM, Braunwald E; TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy)--Thrombolysis in Myocardial Infarction 18 Investigators.. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344(25):1879-87.
Lagerqvist B, Husted S, Kontny F, Näslund U, Ståhle E, Swahn E, Wallentin L; Fast Revascularization during InStability in Coronary artery disease-II Investigators. A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: two-year follow-up of the FRISC-II invasive study. J Am Coll Cardiol. 2002;40(11):1902-14.
Levitsky S. Protecting the myocardial cell during coronary revascularization. The William W. L. Glenn Lecture. Circulation. 2006;114(1 Suppl):I339-43.
Kart A, Yapar K, Karapehlivan M, Citil M. The Possible Protective effect of L‐carnitine on Tilmicosin‐induced Cardiotoxicity in Mice. J Vet Med A Physiol Pathol Clin Med. 2007;54(3):144-6.
Moselhy SS, Demerdash SH. Serum free L-carnitine in association with myoglobin as a diagnostic marker of acute myocardial infarction. Clin Biochem. 2009;42(1-2):78-82.
Atas E, Kismet E, Kesik V, Karaoglu B, Aydemir G, Korkmazer N, Demirkaya E, Karslioglu Y, Yurttutan N, Unay B, Koseoglu V, Gokcay E. Cardiac troponin-I, brain natriuretic peptide and endothelin-1 levels in a rat model of doxorubicin-induced cardiac injury. J Cancer Res Ther. 2015;11(4):882.
Mustafa HN, Hegazy GA, El Awdan SA, AbdelBaset M. Protective role of CoQ10 or L-carnitine on the integrity of the myocardium in doxorubicin induced toxicity. Tissue Cell. 2017;49(3):410-26.
- Abstract Viewed: 265 times
- PDF Downloaded: 175 times